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Cryptic exon activation by disruption of exon splice enhancer:
novel mechanism causing 3-methylcrotonyl-CoA carboxylase
deficiency
Abstract
3-Methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine
catabolism. MCC is a heteromeric mitochondrial enzyme composed of biotin-containing alpha (MCCA)
and smaller beta (MCCB) subunits encoded by MCCA and MCCB, respectively. We report studies of
the c.1054G-->A mutation in exon 11 of MCCB detected in the homozygous state in a patient with
MCC deficiency. Sequence analysis of MCCB cDNA revealed two overlapping transcripts, one
containing the normal 73 bp of exon 11 including the missense mutation c.1054G-->A (p.G352R), the
other with exon 11 replaced by a 64-bp sequence from intron 10 (cryptic exon 10a) that maintains the
reading frame and is flanked by acceptable splice consensus sites. In expression studies, we show that
both transcripts lack detectable MCC activity. Western blot analysis showed slightly reduced levels of
MCCB using the transcript containing the missense mutation, whereas no MCCB was detected with the
transcript containing the cryptic exon 10a. Analysis of the region harboring the mutation revealed that
the c.1054G-->A mutation is located in an exon splice enhancer sequence. Using MCCB minigene
constructs to transfect MCCB-deficient fibroblasts, we demonstrate that the reduction in utilization of
exon 11 associated with the c.1054G-->A mutation is due to alteration of this exon splice enhancer.
Further, we show that optimization of the weak splice donor site of exon 11 corrects the splicing defect.
To our knowledge, this is the first demonstration of a point mutation disrupting an exon splice enhancer
that causes exon skipping along with utilization of a cryptic exon.
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3-Methylcrotonyl-CoA carboxylase (MCC) 
deficiency is an autosomal recessive disorder of 
leucine catabolism. MCC is a heteromeric 
mitochondrial enzyme composed of biotin-
containing α (MCCA) and smaller β (MCCB) 
subunits encoded by MCCA and MCCB, 
respectively. We report studies of the 
c.1054G>A mutation in exon 11 of MCCB 
detected in the homozygous state in a patient 
with MCC deficiency. Sequence analysis of 
MCCB cDNA revealed two overlapping 
transcripts, one containing the normal 73 bp of 
exon 11 including the missense mutation 
c.1054G>A (p.G352R), the other with exon 11 
replaced by a 64 bp sequence from intron 10 
(cryptic exon 10a) that maintains the reading 
frame and is flanked by acceptable splice 
consensus sites. In expression studies we show 
that both transcripts lack detectable MCC 
activity. Western blot analysis showed slightly 
reduced levels of MCCB using the transcript 
containing the missense mutation while no 
MCCB was detected with the transcript 
containing the cryptic exon 10a. Analysis of the 
region harboring the mutation revealed that the 
c.1054G>A mutation is located in an exon splice 
enhancer sequence. Using MCCB-minigene 
constructs to transfect MCCB-deficient 
fibroblasts we demonstrate that the reduction 
in utilization of exon 11 associated with the 
c.1054G>A mutation is due to alteration of this 
exon splice enhancer. Further, we show that 
optimization of the weak splice donor site of 
exon 11 corrects the splicing defect. To our 
knowledge this is the first demonstration of a 
point mutation disrupting an exon splice 
enhancer that causes exon skipping along with 
utilization of a cryptic exon. 
Accurate and efficient removal of introns from 
pre-mRNA is essential for gene expression. The 
information present in the consensus splice site 
signals – the 5’ splice site, branch site and 3’ 
splice site – is necessary but not always sufficient 
to define exon-intron boundaries (1,2). On 
average, these signals appear to provide about half 
of the information required for exon and intron 
recognition in human transcripts (3). Sequences 
flanked by consensus splice site sequences but not 
known to be retained in mature transcripts are 
common in introns; some may be “cryptic exons” 
that for unknown reasons are not normally 
included in mature mRNAs; others may be “true” 
exons that have not been recognized because they 
are alternatively spliced in some developmental or 
tissue-specific fashion (1,4,5). 
Additional cis-acting sequence elements that 
function as splicing enhancers and silencers exist 
in the genome (6). Exon splice enhancers (ESEs)1 
are short sequences within exons that augment 
exon recognition and the control of alternative 
splicing (1). ESEs bind SR proteins, a family of 
essential splicing proteins which activate splicing 
by defining exons and recruiting the splicing 
machinery to the adjacent intronic splice 
consensus sequence (6-8). ESEs appear to be 
common and are present in most, if not all exons 
including constitutive exons (6,9). Unlike 
transcriptional enhancers, ESEs function in a 
strongly position-dependent manner, enhancing 
splicing when present downstream of a 3’ splice 
site or upstream of a 5’ splice site. Other cis-acting 
sequences, often in introns, repress exon 
recognition (6,10). In some instances ESEs appear 
to compensate for “weak” 5’ or 3’ splice signals in 
introns. Strengthening of the splice consensus sites 
of an enhancer-dependent exon by site directed 
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mutagenesis may eliminate dependence on the 
enhancer (8,10). 
Single nucleotide substitutions in the coding 
regions of genes are the most commonly 
recognized type of mutation underlying inherited 
human diseases (11). The molecular 
pathophysiology of nonsense mutations results 
from a combination of premature termination of 
translation and nonsense-mediated mRNA decay 
(NMD) (12,13). The NMD pathway is activated 
by nonsense mutations (or frame shifting deletions 
or insertions) that occur 5’ of the last exon-intron 
junction and minimizes the potential for problems 
caused by truncated proteins by reducing the 
abundance of the abnormal transcript (12,13). The 
deleterious effects of missense mutations are 
usually attributed to their effects on protein 
stability, folding or function (14) while 
synonymous mutations are often assumed to have 
no pathophysiologic consequences. Recently, our 
understanding of the potential pathological effects 
of single nucleotide substitutions has been 
expanded to include alterations that inactivate 
ESEs causing exon skipping (10,15-17). The 
importance of considering the possibility of RNA-
processing phenotypes in the analysis of the 
consequences of mutations is emphasized by the 
growing list of exonic variations that alter RNA-
processing and thereby cause or modify disease 
(see list of 34 “missense” and 26 “silent” point 
mutations causing exon skipping reviewed in (6)). 
3-methylcrotonyl-CoA carboxylase (MCC, EC 
6.4.1.4) is a heteromeric mitochondrial enzyme 
composed of biotin-containing α subunits and 
smaller β subunits, encoded by MCCA (MCCC1; 
MIM 609010) and MCCB (MCCC2; MIM 
609014), respectively (18). Mutations in these 
genes can cause isolated MCC deficiency (MIM 
210200 and 210210), a disorder of leucine 
catabolism inherited as an autosomal recessive 
trait with a variable phenotype that ranges from 
neonatal onset with severe neurological 
involvement to asymptomatic adults (11,18,19). 
Introduction of tandem mass spectrometry to 
newborn screening has resulted in a large increase 
in the number of inborn errors that can be 
detected, including several amino acidemias and 
organic acidurias. This technique has shown MCC 
deficiency to be one of the more frequently 
detected organic acidurias with an overall 
frequency of approximately 1 in 50,000 and a 
mainly mild phenotype (19,20).  
Here we report detailed studies of a missense 
mutation (c.1054G>A, p.G352R) in exon 11 of 
MCCB that disrupts an ESE and causes MCC 
deficiency by utilization of a cryptic exon instead 
of the normal MCCB exon 11. The patient in 
which this mutation was detected (MCC019) is the 
child of a consanguineous union and presented at 
7 months with failure to thrive (19). 
 
EXPERIMENTAL PROCEDURES 
 
Cell cultures and carboxylase assays - Skin 
fibroblasts were cultured in Dulbecco’s 
(transfected cells) or Earl’s minimal essential 
medium supplemented with 10% fetal calf serum, 
2mM L-glutamine and antibiotics. To be able to 
sequence unstable transcripts nonsense mediated 
mRNA decay (NMD) was inhibited by adding 
emetine (100 µg/ml) in the culture medium 10 
hours before harvesting the cells (21). 
Activities of MCC and propionyl-CoA 
carboxylase (PCC) were assayed in fibroblast 
homogenates by measuring the incorporation of 
14C-bicarbonate into acid-non-volatile products 
with established methods (22). 
Mutation analysis by RT-PCR and genomic 
PCR - We extracted RNA and genomic DNA from 
cultured fibroblasts using RNA and DNA isolation 
kits from Qiagen and performed RT-PCR using 2-
5 μg total cellular RNA with the cDNA cycle kit 
(Invitrogen) following the manufacturers’ 
instructions. All PCR reactions (50 μl) contained 
primers (100 ng each), standard PCR buffer 
(Gibco-BRL), dNTPs (200 μM) and Taq 
polymerase (2.5 U; Gibco-BRL). The sequences 
of all primers are listed in supplemental table 1. 
Construction of wild type and mutant MCCB 
expression vectors - To introduce the c.1054G>A 
mutation and the transcript containing the cryptic 
exon (exon 10a) instead of exon 11, we amplified 
cDNA of patient MCC019 with primers DV4498 
and DV4503 and subcloned the PCR products into 
the pTracer-MCCB-wild type construct (18) by 
using the BstEII and SfiI sites. 
MCCB minigene constructs - To examine 
splicing between exons 9 and 12 of the MCCB 
gene, we constructed a MCCB minigene by 
modifying a vector (pBK-RSV-OAT) which had 
previously been shown to function as an in vivo 
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splicing template (12). First a multiple cloning site 
was introduced between the XbaI and the PstI sites 
of the vector. Then an 8.9 kb fragment containing 
the genomic DNA sequence between the 3’ end of 
exon 9 (DV5050) and the 5’ end of exon 12 
(DV5049) of MCCB was amplified from genomic 
DNA of patient MCC019. This sequence was now 
introduced into the multiple cloning site at the 
SpeI and SacI sites (Fig. 3a). 
To optimize the donor splice site of MCCB intron 
11 (CAGgtataa), we used site directed 
mutagenesis to change it into the consensus donor 
sequence (CAGgtaagt) (Fig. 3a). To do this 
overlapping forward (DV5111) and reverse 
(DV5112) primers containing both the c.1054G>A 
mutation and an optimized intron 11 donor splice 
site (c.1072+4 taa>agt) were designed. Primer 
DV5111 was used with a reverse primer in intron 
11 (DV5094) producing a 1952 bp genomic 
fragment containing a XmaI site. Primer DV5112 
was used with a forward primer in intron 10 
(DV5110) amplifying a 1381 bp genomic 
fragment containing a XcaI site. These two PCRs 
were combined and amplified by using the outer 
primers DV5110 and DV5094, producing a 3233 
bp genomic fragment containing both the 
c.1054G>A mutation and an optimized donor 
splice site of intron 11. This fragment was 
subloned into pBK-MCCB-G352R using the XcaI 
and XmaI sites to obtain the pBK-MCCB-
G352RΔss construct. 
Similarly, to introduce the wild type sequence, we 
amplified a 3233 bp genomic fragment from 
control DNA and subcloned it into the pBK-
MCCB-G352R construct. 
We verified that all the inserts and constructs had 
the indicated changes and stayed in frame by 
sequencing all the exons and flanking intronic 
sequences. 
Transfections - For expression studies, the 
constructs were transiently transfected into an 
immortalized MCCB-deficient reference cell line 
by electroporation as described (19). The reference 
cell line originates from skin fibroblasts of a 
patient homozygous for MCCB Q43X, shows no 
detectable MCC activity and does not express 
detectable MCCB protein. We harvested the cells 
48 hrs after transfection and assayed for MCC and 
PCC activities. 
Protein extraction and Western blot – Cell 
lysates were prepared by harvesting confluent 
fibroblasts from a 75 cm2 flask by trypsinization. 
The cells were washed with 5 ml PBS and 
centrifuged for 5 minutes at 200x g. The pellet 
was resuspended in 150 µl protein extraction 
reagent (M-Per, Piercenet) and homogenized in a 
mortar. The homogenate was centrifuged for 5 
minutes at 14’000x g. The supernatant was 
transferred into a new tube and the protein 
concentration was measured using the A280 
method (Nanodrop; Witec). 
Proteins were separated by SDS-PAGE (50 µg per 
lane) and detected by immunoblotting. Anti-
MCCB (Abnova) was used at a dilution of 1:1000. 
Signals were detected using the ECL detection kit 
(Amersham Biosciences). 4 µg of protein was 
processed similarly as loading control and probed 
with a monoclonal Anti-β-Actin antibody (Sigma). 
 
RESULTS 
 
Patient MCC019 presented with severe 
isolated MCC deficiency shown by deficient MCC 
activity (2.2% of median control value) together 
with normal PCC activity in homogenates of 
primary fibroblasts (Fig. 1). Virtually no MCCB 
protein was detected in fibroblasts by Western 
blotting (Fig. 1). 
Sequence analysis of MCCB RT-PCR cDNA 
of this proband revealed two overlapping 
transcripts (19): one contained the normal 73 bp of 
exon 11 with a missense mutation c.1054G>A 
(p.G352R); in the other, exon 11 was replaced by 
a sequence of 64 bp from intron 10 (MCCB-
exon10a). This cryptic exon maintains the reading 
frame and is flanked by acceptable splice 
consensus sites [ctttagAAA…..ATGgtaagt; 
average score of 86, (23)]. 
Amplification and sequencing of exon 11 from 
genomic DNA showed that the patient was 
homozygous for c.1054G>A (Fig. 2a). However, 
we considered the possibility that the patient had a 
deletion of one MCCB allele being hemizygous for 
MCCB-p.G352R but rejected this possibility 
because the patient is the product of a 
consanguineous union and because Southern blot 
analysis of genomic DNA after digestion with 
several restriction enzymes showed normal 
amounts of MCCB and no fragments of abnormal 
size (not shown). These results indicated that the 
patient indeed carries the missense mutation on 
both alleles. 
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To determine the functional consequences of 
the mutation, we subcloned both transcripts into 
pTracer vector and expressed them in an 
immortalized MCCB-deficient reference cell line 
(Fig. 1). Transfection of the MCCB wild type 
construct restored MCC activity from less than 1% 
of the median control value to 16%. Constructs 
with MCCB-G352R and MCCB-exon10a showed 
no rescue of activity, confirming the functional 
significance of these transcripts. 
Western blot of lysates of cells transfected 
with the MCCB-G352R construct revealed slightly 
reduced levels of MCCB protein compared to 
those transfected with the wild type construct. No 
protein was detectable after transfection with the 
MCCB-exon10a construct (Fig. 1). This finding, 
together with Western blot data of untransfected 
patient fibroblasts, indicates that both variants lead 
to protein that is less stable than the wild type 
protein and in the case of MCCB-exon10a is 
rapidly degraded causing absence of MCC 
activity. 
To visualize and assess the relative abundance 
of the two transcripts, we used primers in exon 10 
(DV5020) and 12 (DV5019) to amplify either a 
114 bp fragment (containing exon 11) or a 105 bp 
fragment (lacking exon 11 but containing the 
cryptic exon 10a) from cDNA and separated the 
products on a 12% acrylamide gel (Fig. 2b). From 
patient RNA the 114 bp and 105 bp fragments 
were produced in the ratio of 3 to 2, respectively, 
whereas only the 114 bp fragment was produced 
from control RNA. Both fragments with similar 
relative levels were also obtained using RNA 
extracted from patients’ lymphoblasts, indicating 
that this result is not specific for fibroblasts (not 
shown). 
The effect of NMD on these steady-state 
levels of MCCB transcripts was investigated by 
repeating RT-PCR amplification in emetine 
treated cells. The most abundant MCCB transcript 
in RNA from emetine-treated patient cells was one 
lacking both exon 11 and exon 10a (Fig. 2c). This 
41 bp transcript (MCCB-∆10a,11) results in a 
frameshift followed by a stop codon. It was 
detected only after amplification of patient’s RNA 
after emetine treatment indicating that it is rapidly 
degraded by NMD under normal circumstances. 
The normal exon 11 motif TATGGA was 
identified as a putative SR protein SRp55 
responsive ESE by two independent web-based 
ESE prediction programs, ESEfinder (24) and 
RESCUE-ESE (25), and has been shown to be 
capable of functioning as an ESE (26). This motif 
is mutated to TATAGA in our patient. We 
therefore hypothesized that the reduction in 
utilization of exon 11 associated with the 
c.1054G>A mutation (Fig. 2b) is due to disruption 
of this ESE. 
To confirm this hypothesis we first 
investigated whether we can reproduce the 
skipping of exon 11 by expressing minigene 
constructs in a MCCB-deficient reference cell line 
(Fig. 3a). After transfection we used primers 
complementary to OAT/exon9 (DV5114) and 
OAT/exon12 (DV5115) to amplify by RT-PCR a 
292 bp fragment containing part of MCCB exon 9, 
exon 10, exon 11, and part of exon 12. Sequencing 
of the products showed that the wild type product 
had the expected size of 292 bp. In contrast, most 
of the product of G352R was 219 bp in lenght and 
lacked exon 11, a phenotype detected in patient’s 
cells only after inhibition of NMD by emetine 
treatment. No fragment with the cryptic exon 10a 
in place of exon 11 was obtained (Fig. 3b). 
ESEs have been associated with exons that 
have weak flanking splice sites (1,8) and the donor 
splice site of intron 11 is indeed weak (score of 68 
as compared to 75-98 for most normal exons (23)). 
To determine if the presence of a stronger donor 
site would reduce dependence on the ESE, we 
expressed a minigene construct containing the 
mutated ESE motif in combination with an 
optimized donor splice site (G352RΔss, Fig. 3a). 
Optimization of the donor splice site indeed 
corrected the splicing defect and led to 
amplification of a normal sized fragment (Fig. 3b). 
These results confirm our hypothesis that 
MCCB c.1054G>A partially disrupts an ESE and 
that a functional ESE is no longer required when 
the splice donor site matches the consensus 
sequence. 
 
DISCUSSION 
 
About half of the disease causing nucleotide 
substitutions have been estimated to lead to 
aberrant splicing (6,16,27). 
Typically, the abnormal splicing results from 
inactivation of a splice site or creation of a new 
splice site, or interference with regulatory cis-
elements, such as splicing enhancers or silencers. 
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Our study of the c.1054G>A (p.G352R) mutation, 
detected in the homozygous state in the MCCB 
gene of patient MCC019, illustrates a mechanism 
by which a missense mutation partially disrupts an 
ESE causing utilization of a cryptic exon (exon 
10a) in place of exon 11. The c.1054G>A 
mutation is located in the center of a putative ESE 
motif responsive to the human SR protein SRp55 
(24,25) and affects a highly conserved amino acid. 
Previous work has shown that ESEs can 
compensate for “weak” 5’ or 3’ splice signals in 
exons and that strengthening of the splice 
consensus sites of an enhancer-dependent exon 
generally eliminates enhancer dependence (10). 
The inclusion of exon 10a in place of exon 11 
does not change the reading frame and results in 
the replacement of the normal 24 amino acid 
sequence encoded by exon 11 by a novel sequence 
of 21 amino acid residues. Our expression studies 
clearly show that MCCB-exon10a produces no 
detectable MCCB, while some albeit slightly 
reduced levels of MCCB is produced by MCCB-
G352R suggesting that the MCCB-exon10a and to 
a lesser extent the MCCB-G352R lead to an 
unstable protein product. This is supported by less 
MCCB protein in patient fibroblasts compared to 
control fibroblasts (Fig. 1). The discrepancy 
between the amount of MCCB protein seen in the 
fibroblasts transfected with wild type MCCB and 
the level of MCC activity could probably be 
explained by the fact that transfection efficiency 
was quite low (9%, data not shown) while at the 
same time the few transfected fibroblasts produced 
massive amounts of MCCB protein due to the 
CMV promoter present in the construct. The active 
MCC complex is a (αβ)6 dodecamer and 
overproduction of one of the subunits could lead to 
incomplete and therefore inactive or only partly 
active complexes. 
The glycine at position 352 is a highly 
conserved amino acid and the possibility that this 
change is a polymorphism has previously been 
ruled out (19). In addition, the region of MCCB 
encoded by exon 11 is thought to be part of the 3-
methylcrotonyl-CoA binding site which gives the 
enzyme its substrate specificity (18). It is highly 
likely that replacement of 24 amino acids in this 
region and a missense mutation within this exon 
leads to failure of 3-methylcrotonyl-CoA binding 
with deleterious functional consequences. 
The most common consequence of point 
mutations that affect splicing is exon skipping 
(16,28). This is especially true for point mutations 
disrupting ESEs (6,15,16,27,29). In our patient, 
we were only able to observed exon skipping after 
suppression of NMD and in our minigene 
expression system. The explanation for the 
predominance of a transcript resulting from exon 
skipping rather than one with inclusion of exon 
10a (as in untreated fibroblast RNA) in our 
minigene system remains unclear. Preliminary 
attempts to correct exon skipping events by 
repairing the sequence of damaged exonic 
enhancers have been proven to be efficient in vitro 
and in vivo (30-32), and hold promise for future 
therapeutic use. 
Cryptic exons have been shown to be activated 
by intronic mutations that either create or 
strengthen splice sites, create a new branch site, or 
are located within a cryptic exon (5,16,33-36). To 
our knowledge this is the first demonstration of an 
exonic point mutation disrupting an ESE that leads 
to skipping of the corresponding exon and at the 
same time activates utilization of a cryptic exon 
from the adjacent intron. Mutations causing 
inclusion of cryptic exons may be more prevalent 
than the current literature suggests. Potential 
cryptic exons are frequent in introns and in some 
genes greatly outnumber genuine exons but are 
normally not included in the mature mRNA (4). 
Detection of these events in disease may be 
overlooked because introns are often excluded 
from mutation analysis and because it is often 
impossible or impractical to utilize cDNA for 
mutation analysis. 
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1The abbreviations used are: MCC, 3-methylcrotonyl-Coenzyme A carboxylase; MCCA, methylcrotonyl-
Coenzyme A carboxylase alpha (synonymous to MCCC1); MCCB, methylcrotonyl-Coenzyme A 
carboxylase beta (synonymous to MCCC2); PCC, propionyl-Coenzyme A carboxylase; MCCA, 
methylcrotonyl-Coenzyme A carboxylase alpha subunit; MCCB, methylcrotonyl-Coenzyme A 
carboxylase beta subunit; ESE, exon splice enhancer; NMD, nonsense-mediated mRNA decay; RT-PCR, 
reverse transcriptase polymerase chain reaction 
 
FIGURE LEGENDS 
 
Fig. 1: Expression of pTracer constructs with MCCB wild type cDNA and both types of mutant cDNA of 
patient MCC019 (G352R and exon10a) in an immortalized MCCB-deficient reference fibroblast cell line. 
Not transfected control and patient MCC019 fibroblasts were also analyzed. Transfections were 
performed by electroporation and cells were harvested 48 hours later for the assay of 3-methylcrotonyl-
CoA carboxylase (MCC) and propionyl-CoA carboxylase (PCC) activities as well as Western blot 
analysis of MCCB using β-Actin as a control. Transfection with the empty vector (vector only) was used 
as a negative control. Values are the mean of parallel determinations form a representative experiment. 
For further details see Experimental Procedures. 
Median control values and range (in brackets) for MCC and PCC activities in 30 different immortalized 
fibroblast cell lines are: MCC: 399 pmol/min/mg protein (220-683); PCC: 660 (309-840) 
 
Fig. 2: Schematic diagram of the splicing defect found in MCC019. Boxes represent exons and dark 
horizontal lines introns. 
2a, Genomic PCR of MCCB exon 11 in MCC019 showing the homozygous mutation 
2b, Schematic diagram and RT-PCR products of the splicing variants 
2c, RT-PCR products after treating the cells with emetine (100 µg/ml) before harvesting the RNA. 
Emetine is used to inhibit nonsense mediated mRNA decay (21) 
 
Fig. 3: In vivo splicing analysis. Boxes represent exons and dark horizontal lines introns. The relevant 
portion of exon 11 and its 3’ flanking splice site is shown for three minigene constructs; wild type, 
c.1054G>A (G352R) and c.1054G>A with the optimized donor splice site (G352RΔss). Intronic 
sequences are shown in lower-case, mutated nucleotides are bold. 
3a, Schematic diagram of the three minigene constructs and the primers used for RT-PCR analysis 
3b, RT-PCR products after transfecting MCCB-deficient reference fibroblasts with the indicated minigene 
constructs and the corresponding exon arrangements 
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Figure 3 
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